The FLT3 internal tandem duplication (ITD) mutation (FLT3ITD) is present in nearly one-third of AML cases and has been associated with adverse clinical outcomes including increased relapse risk and decreased overall survival (OS) [8]. FLT3ITD presence in CN-AML identified a subgroup of patients with more adverse outcome, particularly patients with a high mutant allelic frequency [9]. The gene discussed is FLT3; the disease is acute myeloid leukemia.